Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 4/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15092577 | 1.00 | AAK1 (0.53) | AAK1CTSSCTSKCTSBAPLNR | |
| SCHEMBL29784722 | 1.00 | AAK1 (0.53) | AAK1CTSSCTSKCTSBAPLNR | |
| SCHEMBL15092806 | 0.85 | AAK1 (0.51) | AAK1CTSSCTSKCTSB | |
| SCHEMBL2545345 | 0.81 | FPR2 (0.41) | APLNR | |
| SCHEMBL29373654 | 0.81 | AAK1 (0.57) | AAK1CTSSCTSKAPLNR | |
| SCHEMBL9947819 | 0.81 | AAK1 (0.57) | AAK1CTSSCTSKAPLNR | |
| SCHEMBL21456250 | 0.81 | AAK1 (0.57) | AAK1CTSSCTSKAPLNR | |
| SCHEMBL15092375 | 0.81 | AAK1 (0.57) | AAK1CTSSCTSKAPLNR | |
| SCHEMBL30578931 | 0.81 | AAK1 (0.57) | AAK1CTSSCTSKAPLNR | |
| SCHEMBL2799308 | 0.79 | AAK1 (0.52) | AAK1CTSSCTSKCTSBSERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| CN-102917590-A | Trycyclic compounds and pbk inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | AAK1 347/4885CTSS 1540/4885CTSK 144/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | AAK1 347/4885CTSS 1540/4885CTSK 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.